Clinical Trial · NCT06980506

MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

Overview

The purpose of this Expanded Access Program (EAP) is to allow use of the investigational imaging agent, MNPR-101-DFO\*-89Zr, with positron emission tomography/computed tomography (PET/CT) imaging, to non-invasively detect the presence of urokinase plasminogen activator receptor (uPAR) binding in solid tumors. uPAR binding is higher in tumors compared to normal tissue in some cancers.

Sponsor

Fortis Therapeutics

Contacts

Ebrahim S. Delpassand, M.D. Chairman & Medical Director, Nuclear Medicine (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT06980506

Drug / Compound

MNPR-101

Isotope(s):

Target(s):

uPAR

Ligand Class: Antibodies

Chelator: DFO

Eligibility

Inclusion

Histologically or cytologically confirmed locally advanced or metastatic solid tumor cancer that is refractory to existing therapy(ies) known to provide clinical benefit, or for which no standard treatment is available, or is contraindicated

Exclusion

Continuing ≥ Grade 3 adverse reactions from prior systemic therapy (Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0)
Evidence of impaired organ function, particularly bone marrow, liver, kidney, or heart, according to specific test parameters
Prior treatment with any radiopharmaceutical or investigational agents within 4 weeks or 5 half-lives, whichever is longer, prior to administration of MNPR-101-DFO\*-89Zr
Presence of other serious, non-malignant diseases or any other condition that, in the opinion of the investigator, could interfere with the objectives of the study, participant safety, or compliance.